AKBA vs. NAMS, IDYA, SDGR, TVTX, BLTE, VERA, IOVA, PRAX, GLPG, and WVE
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Akebia Therapeutics vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
NewAmsterdam Pharma presently has a consensus price target of $41.60, indicating a potential upside of 124.02%. Akebia Therapeutics has a consensus price target of $7.50, indicating a potential upside of 316.67%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than NewAmsterdam Pharma.
NewAmsterdam Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
NewAmsterdam Pharma has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%.
Akebia Therapeutics received 392 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 63.41% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has higher revenue and earnings than NewAmsterdam Pharma.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for Akebia Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.71 beat Akebia Therapeutics' score of 0.43 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
Summary
NewAmsterdam Pharma beats Akebia Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKBA) was last updated on 2/21/2025 by MarketBeat.com Staff
Free AKBA Stock Alerts